In-licensing of NXC-201 transforms Immix into a mid-to-late stage BCMA-targeting CAR-T therapy with a differentiated tolerability profile. First and only CAR-T therapy in clinical development for AL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback